Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose R-CHOP in Elderly DLBCL
NCT02792491Phase 2Unknown
- Sponsor
- Pusan National University Hospital
- Start
- Aug 2012
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Pusan National University Hospital. Primary endpoint: Progression Free Survival at 3 years. Status: unknown.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02792491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792491.